Email Print Friendly Share Houston, TX, Feb. 24, 2020 (GLOBE NEWSWIRE) - Excel Diagnostics and Nuclear Oncology Center (EDNOC) announced today that its physician sponsored Investigational New Drug (IND) application to evaluate safety and efficacy of Lu-177 DOTATOC in adult subjects with Somatostatin receptor (SSTR) expressing Pulmonary, pheochromocytoma, Paraganglioma, Unknown primary, and Thymus Neuroendocrine Tumors...Read More →
